In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Background Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated
into the clinical management of patients with advanced cancer. Beyond tumor profiling …

Purpose: The summary presented herein represents Part I of the two-part series dedicated to
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and …

Bone metastases are a frequent and severe complication of advanced-stage cancers. Breast
and prostate cancers, the most common malignancies in women and men, respectively …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

Subclinical prostate cancer is common in men> 50 years. Population-based screening of
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …

Prostate cancer affects one in every nine men in the USA and is the second leading cause of
cancer-related death. The treatment landscape of advanced prostate cancer is changing …